| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-06-08 | Viaskin® Peanut | peanut allergy | 2 | DBV Technologies (France) | Allergic diseases |
| 2015-06-08 | eicosapentaenoic acid | preclinical | Amarin (Ireland) | Cardiovascular diseases - Metabolic diseases | |
| 2015-06-06 | Lyxumia® (lixisenatide) | type 2 diabetes |
3 | Sanofi (France) Zealand Pharma (Denmark) | Metabolic diseases |
| 2015-06-06 | Trulicity® (dulaglutide) | type 2 diabetes |
3 | Eli Lilly (USA - IN) | Metabolic diseases |
| 2015-06-06 | imeglimin | type 2 diabetes | 2b | Poxel (France) | Metabolic diseases |
| 2015-06-06 | Novo Nordisk (Denmark) | ||||
| 2015-06-06 | Victoza® (liraglutide) | type 2 diabetes | Novo Nordisk (Denmark) | Metabolic diseases | |
| 2015-06-04 | BLZ-100 - chlorotoxin conjugated to indocyanine green dye | brain tumor |
1 | Blaze Biosciences (USA - WA) | Cancer - Oncology - Rare diseases |
| 2015-06-04 | HDM AIT (Mitizax® in Europe - immunotherapy tablet) | house dust mite-induced allergic rhinitis/rhinoconjunctivitis in children and adults |
3 | Merck&Co (USA - NJ) ALK Abello (Denmark) | Allergic diseases - Immune diseases |
| 2015-06-04 | imeglimin | type 2 diabetes | 2 | Poxel (France) | Metabolic diseases |
| 2015-06-04 | Viaskin® Peanut | peanut allergy | 3 - pediatric | DBV Technologies (France) | Allergic diseases |
| 2015-06-04 | burosumab - recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23/KRN23 | X-linked hypophosphatemia (XLH) | 2 | Ultragenyx Pharmaceutical (USA - CA) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2015-06-03 | DEZ-001 - TA-8995 | dyslipidemia | 2b | Dezima Pharma (The Netherlands) | Cardiovascular diseases |
| 2015-06-03 | VR942 | asthma | 1 | Vectura (UK) UCB Pharma (Belgium) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2015-06-03 | CC-220 | systemic lupus erythematosus (SLE) | 1 | Celgene (USA - NJ) | Autoimmune diseases – Inflammatory diseases |
| 2015-06-02 | Yondelis® (trabectedin ) | advanced liposarcoma or leiomyosarcoma | 3 | Janssen Research & Development, a J&J company (USA - NJ) Pharmamar (Spain) | Cancer - Oncology |
| 2015-06-02 | antibiotic designed to tackle Methicillin-Resistant Staphylococcus Aureus (MRSA) | Methicillin-Resistant Staphylococcus Aureus (MRSA) infections | preclinical | RedXPharma (UK) | Infectious diseases |
| 2015-06-02 | elotuzumab | relapsed or refractory multiple myeloma | 3 | BMS (USA - NY) Abbvie (USA - IL) | Cancer - Oncology |
| 2015-06-02 | sacituzumab govitecan - IMMU-132 | metastatic lung cancer | Immunomedics (USA - NJ) | Cancer - Oncology | |
| 2015-06-01 | GTL002 | treatment of women infected with oncogenic HPV types but who have not yet developed high-grade lesions or cervical cancer |
preclinical | Genticel (France) | Cancer - Oncology - Infectious diseases |
